trimetrexate has been researched along with Leukemia, Myeloid in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nusbaum, NJ | 1 |
| Abraham, T | 1 |
1 other study available for trimetrexate and Leukemia, Myeloid
| Article | Year |
|---|---|
AZT modulation of trimetrexate myelotoxicity: evidence from an HL60 model.
Topics: Acquired Immunodeficiency Syndrome; Humans; Leukemia, Myeloid; Models, Biological; Trimetrexate; Tum | 1995 |